Topical Drugs Contract Development and Manufacturing Organization (CDMO) Market Report 2026

The topical drugs contract development and manufacturing organization (cdmo) market size has grown rapidly in recent years. It will grow from $61.16 billion in 2025 to $70.96 billion in 2026 at a compound annual growth rate (CAGR) of 16%. The growth in the historic period can be attributed to growth in pharmaceutical outsourcing, rising prevalence of dermatological conditions, cost optimization by pharmaceutical companies, increasing regulatory complexity, expansion of generic topical drugs.

The topical drugs contract development and manufacturing organization (cdmo) market size is expected to see rapid growth in the next few years. It will grow to $121.22 billion in 2030 at a compound annual growth rate (CAGR) of 14.3%. The growth in the forecast period can be attributed to increasing development of advanced topical therapies, rising demand for transdermal patches, expansion of small and mid-sized pharma pipelines, growing need for scalable manufacturing, increased focus on speed to market. Major trends in the forecast period include rising outsourcing of topical drug manufacturing, growing demand for complex topical formulations, expansion of transdermal drug delivery platforms, increasing focus on regulatory-compliant manufacturing, higher demand for end-to-end CDMO services.

The rising incidence of skin diseases is anticipated to boost the expansion of the topical drugs contract development and manufacturing organization (CDMO) market in the future. Skin diseases are medical conditions impacting the skin, leading to symptoms like inflammation, itching, and lesions. This uptick in skin diseases stems from factors including environmental pollution, UV radiation exposure, genetic factors, lifestyle shifts, and microbial infections. Topical drugs CDMOs contribute to lowering skin disease rates by creating and producing specialized therapies that enhance the treatment and control of dermatological issues. For instance, in 2023, Cancer Australia - a government agency in Australia - reported around 8,257 new diagnoses of skin melanoma, representing 2.6% of all cancer-related deaths. Thus, the growing prevalence of skin diseases is fueling the topical drugs CDMO market's growth.

Major players in the topical drugs CDMO market are investing in cutting-edge manufacturing sites to maintain their competitive edge. A cutting-edge manufacturing site represents a dedicated production hub outfitted with the newest technologies and sophisticated processes, specifically designed for creating and producing topical pharmaceuticals. For example, in November 2023, SOHM Inc., a U.S.-based pharma firm, opened a GMP-compliant CDMO facility. The new Carlsbad site provides generous space for topical product manufacturing and SOHM's activities, including 2,500 square feet for finished goods storage. It starts with a daily output of 500 gallons (1,892 liters) for topicals, with plans to scale up by the end of Q1 2024 or early Q2 2024 to encompass soft-gel suppositories.

In April 2024, CoreRx Inc., a U.S.-based pharmaceutical firm, purchased Societal CDMO Inc. for $130 million. This deal aims to bolster CoreRx as a more robust CDMO, broadening its offerings from early-stage development through to commercial production. It promises to optimize operations, boost market presence, and deliver enduring advantages like enhanced economies of scale, superior R&D capabilities, and a firmer competitive edge. Societal CDMO Inc. is a U.S.-based contract development and manufacturing organization focused on creating and producing innovative drug delivery formulations.

Major companies operating in the topical drugs contract development and manufacturing organization (cdmo) market are Catalent Inc., Lonza Group AG, Recipharm AB, Piramal Pharma Solutions, Cambrex Corporation, PCI Pharma Services, Famar S.A., Contract Pharmaceuticals Limited, UPM Pharmaceuticals Inc., MedPharm Ltd, Tergus Pharma LLC, NextPharma Technologies Holding Limited, Bora Pharmaceuticals Co. Ltd., LTS Lohmann Therapie-Systeme AG, CoreRx Inc., Halo Pharmaceutical Inc., Tapemark Company, Groupe PARIMA Inc., Dow Development Laboratories LLC, Tedor Pharma Inc.

Asia-Pacific was the largest region in the topical drugs contract development and manufacturing organization (CDMO) market in 2025. The regions covered in the topical drugs contract development and manufacturing organization (cdmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the topical drugs contract development and manufacturing organization (cdmo) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the topical drugs CDMO market by increasing costs of imported excipients, packaging materials, and specialized manufacturing equipment. Semi-solid and transdermal product segments are most affected, particularly in regions dependent on cross-border sourcing such as Asia-Pacific and Europe. Higher tariffs may raise contract manufacturing costs and extend development timelines. However, tariffs are encouraging localized manufacturing investments and supply chain diversification.

The topical drugs contract development and manufacturing organization (cdmo) market research report is one of a series of new reports that provides topical drugs contract development and manufacturing organization (cdmo) market statistics, including topical drugs contract development and manufacturing organization (cdmo) industry global market size, regional shares, competitors with a topical drugs contract development and manufacturing organization (cdmo) market share, detailed topical drugs contract development and manufacturing organization (cdmo) market segments, market trends and opportunities, and any further data you may need to thrive in the topical drugs contract development and manufacturing organization (cdmo) industry. This topical drugs contract development and manufacturing organization (cdmo) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A topical drugs CDMO is a specialized firm offering end-to-end services for developing, formulating, and manufacturing topical pharmaceuticals. These services cover research and development, production of clinical trial materials, and commercial-scale manufacturing. CDMOs enable pharmaceutical companies to efficiently and compliantly launch topical drug products to market.

The primary product categories offered by topical drug contract development and manufacturing organizations (CDMOs) consist of semi-solid formulations, liquid formulations, solid formulations, and transdermal products. Semi-solid formulations encompass creams, ointments, gels, and pastes intended for topical use. A range of service types is available, including contract development and contract manufacturing across diverse therapeutic fields like dermatology, pain management, wound care, and ophthalmology, among others. These are utilized by various end-users, such as pharmaceutical companies, biopharmaceutical companies, and additional entities.

The topical drugs contract development and manufacturing organization (CDMO) market consists of revenues earned by entities by providing services such as commercial manufacturing, research and development (R&D), regulatory support, and product lifecycle management. The market value includes the value of related goods sold by the service provider or included within the service offering. The topical drugs contract development and manufacturing organization (CDMO) market also includes sales of creams, ointments, gels, and lotions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.